Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI Redifferentiation Therapy in Patients With RAIR Thyroid Cancer
NCT05182931Phase 2Recruiting
- Sponsor
- Olivia Newton-John Cancer Research Institute
- Start
- Jul 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of trametinib and dabrafenib + trametinib in thyroid cancer (2 arms), sponsored by Olivia Newton-John Cancer Research Institute. Primary endpoint: Progression-Free Survival at 12 months. Started Jul 2022; status: recruiting.
02
Drugs
trametinibdabrafenib + trametinib
03
Conditions
thyroid cancer
Beyond the preview
Go deeper on NCT05182931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05182931.